Alternative Medicine Shop     
 
Home Products Research Articles View Shopping Cart Contact us
 
 

To order by phone, call toll-free 1-800-530-3775

 

 

Non-Hormonal Treatment of Osteoporosis Restores Bone Density and Halts Bone Loss

Prevention and Treatment of Bone Loss with Hydroxyapatite

Microcrystalline Calcium Hydroxyapatite Complex (M.C.H.C.) has been used with great clinical success in the prevention and treatment of accelerated bone loss due to osteoporosis, not only to prevent and halt bone loss, but also to restore bone density.(1,4)

M.C.H.C. has been shown to:

  • Restore bone density by promoting positive bone balance and net remineralization of bone in both axial and appendicular skeleton due to superior absorption and reduction in endosteal cortical bone resorption.(1,4)

  • Reduce the risk of bone loss in metabolic bone diseases including osteoporosis, osteomalacia and rickets.(10)

  • Reduce the rate of progression of osteoporosis resulting from aging, dietary calcium deficiency and secondary pathologies.(10)

  • Produce favorable biochemical and radiological bone changes which lessen skeletal pain in patients developing osteoporosis.(9)

  • Reduce the incidence of fractures and facilitate healing of fractures.(9)

Effective Natural Therapy for Osteoporosis Patients

Osteoporosis is characterized by decreased bone density with increased susceptibility to fractures. Bone loss coincides with decreased physical activity in both sexes in later years and is vigorously aggravated by age-associated hormonal changes in women and chronic inadequate dietary intake of calcium.

However, osteoporosis is not limited to "natural" aging and dietary deficiency. Secondary pathologies can also induce bone mineral loss. Demineralization and cortical bone thinning always occur in primary biliary cirrhosis patients and osteoporosis is one of the principal complications of long--term corticosteroid treatment for respiratory problems and rheumatoid arthritis.(2,4,7,9)

Calcium supplements, sodium fluoride and estrogens are the only agents whose ability to influence favorably the process of osteoporosis has been established. Of these, only calcium is without potential hazards.(9)

Sodium fluoride improves mineralization of bone, but also induces osteomalacia. This can be counteracted by simultaneous treatment with calcium and vitamin D. Other side effects of sodium fluoride therapy include gastrointestinal intolerance and rheumatic symptoms such as transient synovitis and plantar facitis.(1,3)

In comparison studies, M.C.H.C. was shown to increase serum calcium levels nearly twice as much as calcium gluconate and significantly more than ashed bone.(4,9,13) Increased serum calcium has been shown to suppress production of parathyroid hormone and decrease bone resorption.(9)

Boron Reduces Calcium Excretion

A 1986 study to examine the effects of boron on major mineral metabolism in postmenopausal women, showed that daily supplementation with 3 mg. of boron markedly reduced urinary excretion of calcium and magnesium. In addition, a significant increase was seen in the blood levels of both estrogen and testosterone.(14)

Estrogen therapy has been used for postmenopausal women to suppress the resorption of bone induced by a nocturnal surge of parathyroid hormone.(13)

All Calcium Supplements Are Not Created Equal

Several forms of calcium are found in supple-ments. The least expensive and most readily available, calcium carbonate, has the advantage of an antacid effect in the stomach, but the disadvantages of producing carbon dioxide and of interfering with digestion. Soluble calcium gluconate is similar but more palatable.(1)

Dr. Ralph F. Shangraw, Chairman of the Department of Pharmaceutics at the University of Maryland School of Pharmacy, tested more than 80 of the calcium carbonate supplements on the market and found that the "effectiveness of over half of the tablets is questionable" due to their slow rate of disintegration and dissolution.(8)

M.C.H.C. displays superior absorptive performance compared to other forms of calcium and has been shown, in animal studies, to present no hematological, biochemical or morphological signs of toxicity and no significant adverse effects have ever been reported in human use. In a comparison of microcrystalline hydroxyapatite and calcium gluconate, calcium gluconate halted bone loss but did not restore it, whereas M.C.H.C. did restore bone.(1,4)

M.C.H.C. is prepared from raw bone by a special low temperature process (below 37C) to preserve the natural protein content. The calcium thus provided is an extremely bioavailable form. In addition, the product contains trace amounts of minerals such as boron, magnesium, zinc, potassium, manganese, fluorine (as fluorapatite), silica, iron and magnesium in the natural ratios occurring in normal bone.(1,5) Because of its positive effect on bone remineralization, 0.75 mg. of boron has been added to each tablet.

Reduce Risk Factors Osteoporosis Is Not Inevitable

Most adults lose minerals from bone steadily throughout their lives. In women this bone loss is accelerated for a year or two after menopause, but osteoporosis is not inevitable and some people do not lose bone.(1,6)

Of course, the best cure for osteoporosis is prevention.(11,12) The first step in prevention is to identify those at risk and then to eliminate as many risk factors as possible. Studies now suggest that an intake of 1,500 mg. daily after menopause and 1,000 mg. daily before menopause is necessary to maintain calcium equilibrium in women.(1)

Note: Vitamin D is intentionally left out of this product. Many experts believe the average diet is already overdosed with Vitamin D fortified foods.

WARNING: This publication and the product contained herein have not been approved or evaluated by the Food and Drug Administration. This publication, and the product contained herein are not intended to diagnose, treat, cure or prevent any disease. The product relates to nutritional support only.

M.C.H.C.
Microcrystalline Calcium Hydroxyapatite Complex

Each tablet provides: % Daily Value
Calcium 250 mg. 25%
From 500 mg. M.C.H.C. 125 mg.
From 500 mg. Calcium Citrate 125 mg.
Phosphorus (from M.C.H.C.) 65 mg. 6%
Magnesium (from M.C.H.C.) 4 mg. 1%
Zinc (from M.C.H.C.) 0.075 mg. <1%
Copper (from M.C.H.C.) 0.01 mg. <1%
Manganese (from M.C.H.C.) 0.045 mg. <1%
Potassium (from M.C.H.C.) 0.035 mg. <1%
Protein (from microcrystalline hydroxyapatite as collagen glycosaminoglycans) 125 mg. <1%
Boron (as aspartate) 750 mcg. *
Fluorapatite (from M.C.H.C.) 31 mcg. *
Silicon (from M.C.H.C.) 19 mcg. *
Strontium (from M.C.H.C. 10 mcg. *
Other ingredients: Vegetable cellulose, vegetable stearate, gelatin. *Daily Value not established.

Recommended Dosage: Four tablets daily to supply 100% of the U.S. R.D.I. for calcium. M.C.H.C. also increases amounts of phosphorus and other natural bone components in the diet. Tablets should be taken before meals.

   
   


or CALL TOLL FREE:
1-800-530-3775
 
The Alternative Medicine Shop

REFERENCES

1. Dixon, A.S., Non-Hormonal Treatment of Osteoporosis, British Medical Journal, Vol. 286, No. 6370, March 26, 1983.

2. Nilsen, K.H., Jayson, M., Dixon, A.S., Microcrystalline Calcium Hydroxyapatite compound in corticosteroid-treated rheumatoid patients:  Controlled Study. British Medical Journal, 1978.

3. Hansson, T., Roos, B., Paper given at workshop on dual photon absorption, San Francisco, CA, Jan. 16, 1982

4. Epstein, O., Kato, Y., Dick, R., Sherlock, S., Vitamin D, hydroxyapatite and calcium gluconate in Treatment of Cortical Bone Thinning in Post-menopausal Women with Primary Biliary Cirrhosis. American Journal of Clinical Nutrition, Vol. 36:426-30.

5. Windsor, A.C.M., Misra, D.P., Loudon, J.M., Staddon, G.E., The Effect of Whole Bone Extract on 47Ca Absorption in the Elderly, Age and Aging, 1973:1:230.

6. Adams, P., Davies, G.T., Sweetnam, P., Osteoporosis and the Effects of Aging on Bone Mass in Elderly Men and Women, QJ Med. 70;39:601-1.

7. Stellon, A., et. al., Postgrad Med. Journal, 1985;61:791-796.

8. Shangraw, R. F., Conference on Osteoporosis, F.D.A. Oct., 1987.

9. Pines, A., et. al., Curr Med. Res. Opinion, 1984;8:734-742.

10. Stamp, T.C.B., Calcitron Dosage in Osteomalacia, Hypoparathyroidism and Attempted Treatment of Myositis Ossificans Progressiva, Curr. Med. Res. Opin., 1981, 7,316.

11. Lindsay, R., Hart, D.M., Aitken, J.M., MacDonald, E.B., Anderson, J.B., Long-term Prevention of postmenopausal osteoporosis by estrogen. Evidence of an increased bone mass after delayed onset of estrogen treatment. Lancet 1976;1:1038-41.

12. Horsman, A., Gallagher, J.C., Simpson, M., Nordin, B.E.C., Prospective Trial Estrogen and Calcium in Postmenopausal Women. British Medical Journal, 1977, 789-92.

13. Durance, R.A., et. al., Treatment of Osteoporotic Patients A trial of Calcium Supplements and Ashed Bone, Clinical Trials Journal, No. 3, 1973.

4. Nielsen, F.H., et. al., Effect of Dietary Boron on Mineral, Estrogen and Testosterone Metabolism in Postmenopausal Women, April, 1987.

 
 Copyright 2004 Alternative Medicine Shop, LLC. All rights reserved.